Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Feltz-Cornelis, C. Feltz-Cornelis, Danielle Varley, Victoria Allgar, Victoria Allgar, E. Beurs (2020)
Workplace Stress, Presenteeism, Absenteeism, and Resilience Amongst University Staff and Students in the COVID-19 LockdownFrontiers in Psychiatry, 11
COVID: why experts say herd immunity is still out of reach
A. Gandjour (2021)
How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in GermanyApplied Health Economics and Health Policy, 19
(Bundesministerium für Wirtschaft und Energie. Altmaier: „Rechnen mit Wirtschaftswachstum von 3,5% in 2021 und 3,6% in 2022“. https://www.bmwi.de/Redaktion/DE/Pressemitteilungen/2021/04/20210427-Altmaier-Rechnen-mit-Wirtschaftswachstum-von-3,5%25-2021-und-3,6%25-2022.html. 2021.)
Bundesministerium für Wirtschaft und Energie. Altmaier: „Rechnen mit Wirtschaftswachstum von 3,5% in 2021 und 3,6% in 2022“. https://www.bmwi.de/Redaktion/DE/Pressemitteilungen/2021/04/20210427-Altmaier-Rechnen-mit-Wirtschaftswachstum-von-3,5%25-2021-und-3,6%25-2022.html. 2021.Bundesministerium für Wirtschaft und Energie. Altmaier: „Rechnen mit Wirtschaftswachstum von 3,5% in 2021 und 3,6% in 2022“. https://www.bmwi.de/Redaktion/DE/Pressemitteilungen/2021/04/20210427-Altmaier-Rechnen-mit-Wirtschaftswachstum-von-3,5%25-2021-und-3,6%25-2022.html. 2021., Bundesministerium für Wirtschaft und Energie. Altmaier: „Rechnen mit Wirtschaftswachstum von 3,5% in 2021 und 3,6% in 2022“. https://www.bmwi.de/Redaktion/DE/Pressemitteilungen/2021/04/20210427-Altmaier-Rechnen-mit-Wirtschaftswachstum-von-3,5%25-2021-und-3,6%25-2022.html. 2021.
(ChallenRBrooks-PollockEReadJM, et al.Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ2021; 372: n579.33687922)
ChallenRBrooks-PollockEReadJM, et al.Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ2021; 372: n579.33687922ChallenRBrooks-PollockEReadJM, et al.Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ2021; 372: n579.33687922, ChallenRBrooks-PollockEReadJM, et al.Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ2021; 372: n579.33687922
(RamseyFP. A mathematical theory of saving. The Econ J1928; 38(152): 543–559.)
RamseyFP. A mathematical theory of saving. The Econ J1928; 38(152): 543–559.RamseyFP. A mathematical theory of saving. The Econ J1928; 38(152): 543–559., RamseyFP. A mathematical theory of saving. The Econ J1928; 38(152): 543–559.
(Van Der Feltz-CornelisCMVarleyDAllgarVL, et al.Workplace stress, presenteeism, absenteeism, and resilience amongst university staff and students in the COVID-19 lockdown. Front Psychiatry2020; 11: 588803.33329135)
Van Der Feltz-CornelisCMVarleyDAllgarVL, et al.Workplace stress, presenteeism, absenteeism, and resilience amongst university staff and students in the COVID-19 lockdown. Front Psychiatry2020; 11: 588803.33329135Van Der Feltz-CornelisCMVarleyDAllgarVL, et al.Workplace stress, presenteeism, absenteeism, and resilience amongst university staff and students in the COVID-19 lockdown. Front Psychiatry2020; 11: 588803.33329135, Van Der Feltz-CornelisCMVarleyDAllgarVL, et al.Workplace stress, presenteeism, absenteeism, and resilience amongst university staff and students in the COVID-19 lockdown. Front Psychiatry2020; 11: 588803.33329135
(PollockAMRoderickPChengKK, et al.Covid-19: why is the UK government ignoring WHO's advice?BMJ2020; 368: m1284.32229543)
PollockAMRoderickPChengKK, et al.Covid-19: why is the UK government ignoring WHO's advice?BMJ2020; 368: m1284.32229543PollockAMRoderickPChengKK, et al.Covid-19: why is the UK government ignoring WHO's advice?BMJ2020; 368: m1284.32229543, PollockAMRoderickPChengKK, et al.Covid-19: why is the UK government ignoring WHO's advice?BMJ2020; 368: m1284.32229543
(Science Magazine. Can you put a price on COVID-19 options? Experts weigh lives versus economics. https://www.sciencemag.org/news/2020/03/modelers-weigh-value-lives-and-lockdown-costs-put-price-covid-19#. 2020.)
Science Magazine. Can you put a price on COVID-19 options? Experts weigh lives versus economics. https://www.sciencemag.org/news/2020/03/modelers-weigh-value-lives-and-lockdown-costs-put-price-covid-19#. 2020.Science Magazine. Can you put a price on COVID-19 options? Experts weigh lives versus economics. https://www.sciencemag.org/news/2020/03/modelers-weigh-value-lives-and-lockdown-costs-put-price-covid-19#. 2020., Science Magazine. Can you put a price on COVID-19 options? Experts weigh lives versus economics. https://www.sciencemag.org/news/2020/03/modelers-weigh-value-lives-and-lockdown-costs-put-price-covid-19#. 2020.
(DimpflTSönksenJBechmannI, et al.Estimation of the SARS-CoV-2 infection fatality rate in Germany. medRxiv. 2021.)
DimpflTSönksenJBechmannI, et al.Estimation of the SARS-CoV-2 infection fatality rate in Germany. medRxiv. 2021.DimpflTSönksenJBechmannI, et al.Estimation of the SARS-CoV-2 infection fatality rate in Germany. medRxiv. 2021., DimpflTSönksenJBechmannI, et al.Estimation of the SARS-CoV-2 infection fatality rate in Germany. medRxiv. 2021.
Lesson 3: measures of risk. Section 6: measures of public health impact
(DamuthEMitchellJABartockJL, et al.Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis. Lancet Respir Med2015; 3(7): 544–553.26003390)
DamuthEMitchellJABartockJL, et al.Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis. Lancet Respir Med2015; 3(7): 544–553.26003390DamuthEMitchellJABartockJL, et al.Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis. Lancet Respir Med2015; 3(7): 544–553.26003390, DamuthEMitchellJABartockJL, et al.Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis. Lancet Respir Med2015; 3(7): 544–553.26003390
(European Commission. Remarks by commissioner gentiloni at the press conference on the Autumn 2020 economic forecast. https://ec.europa.eu/commission/presscorner/detail/en/speech_20_2040. 2020.)
European Commission. Remarks by commissioner gentiloni at the press conference on the Autumn 2020 economic forecast. https://ec.europa.eu/commission/presscorner/detail/en/speech_20_2040. 2020.European Commission. Remarks by commissioner gentiloni at the press conference on the Autumn 2020 economic forecast. https://ec.europa.eu/commission/presscorner/detail/en/speech_20_2040. 2020., European Commission. Remarks by commissioner gentiloni at the press conference on the Autumn 2020 economic forecast. https://ec.europa.eu/commission/presscorner/detail/en/speech_20_2040. 2020.
(SheridanAAndersenALHansenET, et al.Social distancing laws cause only small losses of economic activity during the COVID-19 pandemic in Scandinavia. Proc Natl Acad Sci U S A2020; 117(34): 20468–20473.32747573)
SheridanAAndersenALHansenET, et al.Social distancing laws cause only small losses of economic activity during the COVID-19 pandemic in Scandinavia. Proc Natl Acad Sci U S A2020; 117(34): 20468–20473.32747573SheridanAAndersenALHansenET, et al.Social distancing laws cause only small losses of economic activity during the COVID-19 pandemic in Scandinavia. Proc Natl Acad Sci U S A2020; 117(34): 20468–20473.32747573, SheridanAAndersenALHansenET, et al.Social distancing laws cause only small losses of economic activity during the COVID-19 pandemic in Scandinavia. Proc Natl Acad Sci U S A2020; 117(34): 20468–20473.32747573
(GandjourA. How many intensive care beds are justifiable for hospital pandemic preparedness? A cost-effectiveness analysis for COVID-19 in Germany. Appl Health Econ Health Policy2021; 19(2): 181–190.33433853)
GandjourA. How many intensive care beds are justifiable for hospital pandemic preparedness? A cost-effectiveness analysis for COVID-19 in Germany. Appl Health Econ Health Policy2021; 19(2): 181–190.33433853GandjourA. How many intensive care beds are justifiable for hospital pandemic preparedness? A cost-effectiveness analysis for COVID-19 in Germany. Appl Health Econ Health Policy2021; 19(2): 181–190.33433853, GandjourA. How many intensive care beds are justifiable for hospital pandemic preparedness? A cost-effectiveness analysis for COVID-19 in Germany. Appl Health Econ Health Policy2021; 19(2): 181–190.33433853
D. Khoury, D. Cromer, A. Reynaldi, T. Schlub, A. Wheatley, J. Juno, K. Subbarao, S. Kent, J. Triccas, M. Davenport (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 27
(German National Academy of Sciences. Ökonomische KONSEQUENZEN der CORONAVIRUS-PANDEMIE – DIAGNOSEN und HANDLUNGSOPTIONEN. https://levana.leopoldina.org/receive/leopoldina_mods_00359. 2021.)
German National Academy of Sciences. Ökonomische KONSEQUENZEN der CORONAVIRUS-PANDEMIE – DIAGNOSEN und HANDLUNGSOPTIONEN. https://levana.leopoldina.org/receive/leopoldina_mods_00359. 2021.German National Academy of Sciences. Ökonomische KONSEQUENZEN der CORONAVIRUS-PANDEMIE – DIAGNOSEN und HANDLUNGSOPTIONEN. https://levana.leopoldina.org/receive/leopoldina_mods_00359. 2021., German National Academy of Sciences. Ökonomische KONSEQUENZEN der CORONAVIRUS-PANDEMIE – DIAGNOSEN und HANDLUNGSOPTIONEN. https://levana.leopoldina.org/receive/leopoldina_mods_00359. 2021.
F. Daumann, Florian Follert, Werner Gleißner, Endre Kamarás, Chantal Naumann (2021)
Political Decision Making in the COVID-19 Pandemic: The Case of Germany from the Perspective of Risk ManagementInternational Journal of Environmental Research and Public Health, 19
(FakhruddinBSBlanchardKRagupathyD. Are we there yet? The transition from response to recovery for the COVID-19 pandemic. Prog Disaster Sci2020; 7: 100102.34171013)
FakhruddinBSBlanchardKRagupathyD. Are we there yet? The transition from response to recovery for the COVID-19 pandemic. Prog Disaster Sci2020; 7: 100102.34171013FakhruddinBSBlanchardKRagupathyD. Are we there yet? The transition from response to recovery for the COVID-19 pandemic. Prog Disaster Sci2020; 7: 100102.34171013, FakhruddinBSBlanchardKRagupathyD. Are we there yet? The transition from response to recovery for the COVID-19 pandemic. Prog Disaster Sci2020; 7: 100102.34171013
B. Fakhruddin, Kevin Blanchard, Durga Ragupathy (2020)
Are we there yet? The transition from response to recovery for the COVID-19 pandemicProgress in Disaster Science, 7
COVID-19 pandemic planning scenarios
(Federal Office of Statistics. Allgemeine Sterbetafel 2016/2018. Wiesbaden: Federal Office of Statistics, 2019.)
Federal Office of Statistics. Allgemeine Sterbetafel 2016/2018. Wiesbaden: Federal Office of Statistics, 2019.Federal Office of Statistics. Allgemeine Sterbetafel 2016/2018. Wiesbaden: Federal Office of Statistics, 2019., Federal Office of Statistics. Allgemeine Sterbetafel 2016/2018. Wiesbaden: Federal Office of Statistics, 2019.
The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. Q Rev Econ Finance
L. Garrison, E. Mansley, T. Abbott, B. Bresnahan, J. Hay, J. Smeeding (2010)
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 13 1
(KhouryDSCromerDReynaldiA, et al.Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med2021; 27: 1205.34002089)
KhouryDSCromerDReynaldiA, et al.Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med2021; 27: 1205.34002089KhouryDSCromerDReynaldiA, et al.Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med2021; 27: 1205.34002089, KhouryDSCromerDReynaldiA, et al.Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med2021; 27: 1205.34002089
(GandjourA. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. Q Rev Econ Finance. In print.)
GandjourA. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. Q Rev Econ Finance. In print.GandjourA. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. Q Rev Econ Finance. In print., GandjourA. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. Q Rev Econ Finance. In print.
(2020)
Die Bekämpfung der CORONAVIRUS-PANDEMIE tragfähig gestalten: EMPFEHLUNGEN für eine flexible, risikoadaptierte Strategie
(DysonLHillEMMooreS, et al.Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. medRxiv. 2021.)
DysonLHillEMMooreS, et al.Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. medRxiv. 2021.DysonLHillEMMooreS, et al.Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. medRxiv. 2021., DysonLHillEMMooreS, et al.Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. medRxiv. 2021.
Level of GDP per capita and productivity
Umfrage bei Gesundheitsämtern. Fünf Kontaktpersonen pro Corona-Infiziertem
(2021)
says third covid vaccine dose likely needed within 12 months
(USA Today. Race to the vaccine: a COVID-19 vaccine life cycle: from DNA to doses. https://eu.usatoday.com/in-depth/news/health/2021/02/07/how-covid-vaccine-made-step-step-journey-pfizer-dose/4371693001/. 2021.)
USA Today. Race to the vaccine: a COVID-19 vaccine life cycle: from DNA to doses. https://eu.usatoday.com/in-depth/news/health/2021/02/07/how-covid-vaccine-made-step-step-journey-pfizer-dose/4371693001/. 2021.USA Today. Race to the vaccine: a COVID-19 vaccine life cycle: from DNA to doses. https://eu.usatoday.com/in-depth/news/health/2021/02/07/how-covid-vaccine-made-step-step-journey-pfizer-dose/4371693001/. 2021., USA Today. Race to the vaccine: a COVID-19 vaccine life cycle: from DNA to doses. https://eu.usatoday.com/in-depth/news/health/2021/02/07/how-covid-vaccine-made-step-step-journey-pfizer-dose/4371693001/. 2021.
A. Pollock, P. Roderick, Kk Cheng, B. Pankhania (2020)
Covid-19: why is the UK government ignoring WHO’s advice?BMJ, 368
(GailMBenichouJ. Encyclopedia of epidemiologic methods. Wiley reference series in biostatistics. Chichester: John Wiley & Sons, 2000.)
GailMBenichouJ. Encyclopedia of epidemiologic methods. Wiley reference series in biostatistics. Chichester: John Wiley & Sons, 2000.GailMBenichouJ. Encyclopedia of epidemiologic methods. Wiley reference series in biostatistics. Chichester: John Wiley & Sons, 2000., GailMBenichouJ. Encyclopedia of epidemiologic methods. Wiley reference series in biostatistics. Chichester: John Wiley & Sons, 2000.
Referentenentwurf -Verordnung zum Anspruch auf Schutzimpfung gegen das Coronavirus SARS-CoV-2
(TwohigKANybergTZaidiA, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis2022; 22(1): 35–42.34461056)
TwohigKANybergTZaidiA, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis2022; 22(1): 35–42.34461056TwohigKANybergTZaidiA, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis2022; 22(1): 35–42.34461056, TwohigKANybergTZaidiA, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis2022; 22(1): 35–42.34461056
(Robert Koch Institut. December 29, 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html.)
Robert Koch Institut. December 29, 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html.Robert Koch Institut. December 29, 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html., Robert Koch Institut. December 29, 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html.
Ruben Durante, L. Guiso, G. Gulino (2020)
Asocial capital: Civic culture and social distancing during COVID-19Journal of Public Economics, 194
E. Hanushek, Ludger Woessmann (2020)
The Economic Impacts of Learning Losses. OECD Education Working Papers, No. 225.
Development and licensure of vaccines to prevent COVID-19 guidance for industry
Exports of goods and services (% of GDP
(ChowellGHaymanJMBettencourtLM, et al.Mathematical and statistical estimation approaches in epidemiology. Dordrecht, Heidelberg, London, New York: Springer, 2009.)
ChowellGHaymanJMBettencourtLM, et al.Mathematical and statistical estimation approaches in epidemiology. Dordrecht, Heidelberg, London, New York: Springer, 2009.ChowellGHaymanJMBettencourtLM, et al.Mathematical and statistical estimation approaches in epidemiology. Dordrecht, Heidelberg, London, New York: Springer, 2009., ChowellGHaymanJMBettencourtLM, et al.Mathematical and statistical estimation approaches in epidemiology. Dordrecht, Heidelberg, London, New York: Springer, 2009.
Jianxi Luo (2021)
Forecasting COVID-19 pandemic: Unknown unknowns and predictive monitoringTechnological Forecasting and Social Change, 166
Alexander Rathke, Samad Sarferaz, Sina Streicher, Jan-Egbert Sturm (2020)
Szenario-Analysen zu den kurzfristigen wirtschaftlichen Auswirkungen der COVID-19-Pandemie, 148
(DuranteR.GuisoL.GulinoG.Asocial capital: civic culture and social distancing during COVID-19. J Public Econ2021; 194: 104342.35702335)
DuranteR.GuisoL.GulinoG.Asocial capital: civic culture and social distancing during COVID-19. J Public Econ2021; 194: 104342.35702335DuranteR.GuisoL.GulinoG.Asocial capital: civic culture and social distancing during COVID-19. J Public Econ2021; 194: 104342.35702335, DuranteR.GuisoL.GulinoG.Asocial capital: civic culture and social distancing during COVID-19. J Public Econ2021; 194: 104342.35702335
(World Bank. Exports of goods and services (% of GDP), https://data.worldbank.org/indicator/NE.EXP.GNFS.ZS.)
World Bank. Exports of goods and services (% of GDP), https://data.worldbank.org/indicator/NE.EXP.GNFS.ZS.World Bank. Exports of goods and services (% of GDP), https://data.worldbank.org/indicator/NE.EXP.GNFS.ZS., World Bank. Exports of goods and services (% of GDP), https://data.worldbank.org/indicator/NE.EXP.GNFS.ZS.
(PréziosiMPHalloranME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis2003; 37(6): 772–779.12955637)
PréziosiMPHalloranME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis2003; 37(6): 772–779.12955637PréziosiMPHalloranME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis2003; 37(6): 772–779.12955637, PréziosiMPHalloranME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis2003; 37(6): 772–779.12955637
(Federal Office of Statistics. Vorausberechneter Bevölkerungsstand. Moderate Entwicklung der Geburtenhäufigkeit, Lebenserwartung und Wanderung (G2L2W2). Federal Office of Statistics, 2000.)
Federal Office of Statistics. Vorausberechneter Bevölkerungsstand. Moderate Entwicklung der Geburtenhäufigkeit, Lebenserwartung und Wanderung (G2L2W2). Federal Office of Statistics, 2000.Federal Office of Statistics. Vorausberechneter Bevölkerungsstand. Moderate Entwicklung der Geburtenhäufigkeit, Lebenserwartung und Wanderung (G2L2W2). Federal Office of Statistics, 2000., Federal Office of Statistics. Vorausberechneter Bevölkerungsstand. Moderate Entwicklung der Geburtenhäufigkeit, Lebenserwartung und Wanderung (G2L2W2). Federal Office of Statistics, 2000.
(Tagesschau.de. EMA erteilt Impfstoff grünes Licht. https://ptwww.tagesschau.de/wirtschaft/unternehmen/johnson-impfstoff-ema-einsatz-101.html. 2021.)
Tagesschau.de. EMA erteilt Impfstoff grünes Licht. https://ptwww.tagesschau.de/wirtschaft/unternehmen/johnson-impfstoff-ema-einsatz-101.html. 2021.Tagesschau.de. EMA erteilt Impfstoff grünes Licht. https://ptwww.tagesschau.de/wirtschaft/unternehmen/johnson-impfstoff-ema-einsatz-101.html. 2021., Tagesschau.de. EMA erteilt Impfstoff grünes Licht. https://ptwww.tagesschau.de/wirtschaft/unternehmen/johnson-impfstoff-ema-einsatz-101.html. 2021.
P. F., Ramsey (1928)
THE MATHEMATICAL THEORY OF SAVINGThe Economic Journal, 38
(DenoeuxT. Decision-making with belief functions: a review. Int J Approximate Reason2019; 109: 87–110.)
DenoeuxT. Decision-making with belief functions: a review. Int J Approximate Reason2019; 109: 87–110.DenoeuxT. Decision-making with belief functions: a review. Int J Approximate Reason2019; 109: 87–110., DenoeuxT. Decision-making with belief functions: a review. Int J Approximate Reason2019; 109: 87–110.
(Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19 guidance for industry. https://www.fda.gov/media/139638/download. 2020.)
Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19 guidance for industry. https://www.fda.gov/media/139638/download. 2020.Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19 guidance for industry. https://www.fda.gov/media/139638/download. 2020., Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19 guidance for industry. https://www.fda.gov/media/139638/download. 2020.
(AbersMSMusherDM. Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics. QJM2014; 107(7): 595–596.24803476)
AbersMSMusherDM. Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics. QJM2014; 107(7): 595–596.24803476AbersMSMusherDM. Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics. QJM2014; 107(7): 595–596.24803476, AbersMSMusherDM. Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics. QJM2014; 107(7): 595–596.24803476
(2000)
Encyclopedia of epidemiologic methods. Wiley reference series in biostatistics
(RathkeASarferazSStreicherSSturmJ-E. Szenario-Analysen zu den kurzfristigen wirtschaftlichen Auswirkungen der COVID-19-Pandemie. https://ethz.ch/content/dam/ethz/special-interest/dual/kof-dam/documents/Medienmitteilungen/Prognosen/2020/Corona_Krise.pdf. 2020.)
RathkeASarferazSStreicherSSturmJ-E. Szenario-Analysen zu den kurzfristigen wirtschaftlichen Auswirkungen der COVID-19-Pandemie. https://ethz.ch/content/dam/ethz/special-interest/dual/kof-dam/documents/Medienmitteilungen/Prognosen/2020/Corona_Krise.pdf. 2020.RathkeASarferazSStreicherSSturmJ-E. Szenario-Analysen zu den kurzfristigen wirtschaftlichen Auswirkungen der COVID-19-Pandemie. https://ethz.ch/content/dam/ethz/special-interest/dual/kof-dam/documents/Medienmitteilungen/Prognosen/2020/Corona_Krise.pdf. 2020., RathkeASarferazSStreicherSSturmJ-E. Szenario-Analysen zu den kurzfristigen wirtschaftlichen Auswirkungen der COVID-19-Pandemie. https://ethz.ch/content/dam/ethz/special-interest/dual/kof-dam/documents/Medienmitteilungen/Prognosen/2020/Corona_Krise.pdf. 2020.
G. Chowell, J. Hyman, L. Bettencourt, C. Castillo-Chavez (2009)
Mathematical and statistical estimation approaches in epidemiology
Adam Sheridan, A. Andersen, E. Hansen, Niels Johannesen (2020)
Social distancing laws cause only small losses of economic activity during the COVID-19 pandemic in ScandinaviaProceedings of the National Academy of Sciences, 117
L. Dyson, E. Hill, S. Moore, Jacob Curran-Sebastian, M. Tildesley, K. Lythgoe, T. House, L. Pellis, M. Keeling (2021)
Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristicsNature Communications, 12
(Bundesministerium für Gesundheit. Referentenentwurf - Verordnung zum Anspruch auf Schutzimpfung gegen das Coronavirus SARS-CoV-2. https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/C/Coronavirus/Verordnungen/Corona-ImpfV_190521.pdf. 2021.)
Bundesministerium für Gesundheit. Referentenentwurf - Verordnung zum Anspruch auf Schutzimpfung gegen das Coronavirus SARS-CoV-2. https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/C/Coronavirus/Verordnungen/Corona-ImpfV_190521.pdf. 2021.Bundesministerium für Gesundheit. Referentenentwurf - Verordnung zum Anspruch auf Schutzimpfung gegen das Coronavirus SARS-CoV-2. https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/C/Coronavirus/Verordnungen/Corona-ImpfV_190521.pdf. 2021., Bundesministerium für Gesundheit. Referentenentwurf - Verordnung zum Anspruch auf Schutzimpfung gegen das Coronavirus SARS-CoV-2. https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/C/Coronavirus/Verordnungen/Corona-ImpfV_190521.pdf. 2021.
(NeedhamDMDinglasVDBienvenuOJ, et al.One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. BMJ2013; 346: f1532.23512759)
NeedhamDMDinglasVDBienvenuOJ, et al.One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. BMJ2013; 346: f1532.23512759NeedhamDMDinglasVDBienvenuOJ, et al.One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. BMJ2013; 346: f1532.23512759, NeedhamDMDinglasVDBienvenuOJ, et al.One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. BMJ2013; 346: f1532.23512759
(DaumannFFollertFGleißnerW, et al. Political decision making in the COVID-19 pandemic: the case of Germany from the perspective of risk management. Int J Environ Res Public Health2021; 19(1): 397.35010656)
DaumannFFollertFGleißnerW, et al. Political decision making in the COVID-19 pandemic: the case of Germany from the perspective of risk management. Int J Environ Res Public Health2021; 19(1): 397.35010656DaumannFFollertFGleißnerW, et al. Political decision making in the COVID-19 pandemic: the case of Germany from the perspective of risk management. Int J Environ Res Public Health2021; 19(1): 397.35010656, DaumannFFollertFGleißnerW, et al. Political decision making in the COVID-19 pandemic: the case of Germany from the perspective of risk management. Int J Environ Res Public Health2021; 19(1): 397.35010656
Die vier zugelassenen impfstoffe im VERGLEICH
(HurwiczL. The generalized bayes minimax principle: a criterion for decision making under uncertainty. Cowles Commission Discussion Paper 355. 1951.)
HurwiczL. The generalized bayes minimax principle: a criterion for decision making under uncertainty. Cowles Commission Discussion Paper 355. 1951.HurwiczL. The generalized bayes minimax principle: a criterion for decision making under uncertainty. Cowles Commission Discussion Paper 355. 1951., HurwiczL. The generalized bayes minimax principle: a criterion for decision making under uncertainty. Cowles Commission Discussion Paper 355. 1951.
S. Aum, Sang Lee, Yongseok Shin (2020)
Covid-19 Doesn&Apos;T Need Lockdowns to Destroy Jobs: The Effect of Local Outbreaks in KoreaNBER Working Paper Series
(Abele-BrehmADreierHFuestC, et al.Die Bekämpfung der CORONAVIRUS-PANDEMIE tragfähig gestalten: EMPFEHLUNGEN für eine flexible, risikoadaptierte Strategie. 2020.)
Abele-BrehmADreierHFuestC, et al.Die Bekämpfung der CORONAVIRUS-PANDEMIE tragfähig gestalten: EMPFEHLUNGEN für eine flexible, risikoadaptierte Strategie. 2020.Abele-BrehmADreierHFuestC, et al.Die Bekämpfung der CORONAVIRUS-PANDEMIE tragfähig gestalten: EMPFEHLUNGEN für eine flexible, risikoadaptierte Strategie. 2020., Abele-BrehmADreierHFuestC, et al.Die Bekämpfung der CORONAVIRUS-PANDEMIE tragfähig gestalten: EMPFEHLUNGEN für eine flexible, risikoadaptierte Strategie. 2020.
Zunyou Wu, J. McGoogan (2020)
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.JAMA
Ein freier Markt garantiert keine GE-SUNDHEITSVERSORGUNG. Die Zeit
(European Centre for Disease. Prevention and Control. Weekly surveillance report on COVID-19. 2021, https://www.ecdc.europa.eu/en/covid-19/surveillance/weekly-surveillance-report, 14 October 2021.)
European Centre for Disease. Prevention and Control. Weekly surveillance report on COVID-19. 2021, https://www.ecdc.europa.eu/en/covid-19/surveillance/weekly-surveillance-report, 14 October 2021.European Centre for Disease. Prevention and Control. Weekly surveillance report on COVID-19. 2021, https://www.ecdc.europa.eu/en/covid-19/surveillance/weekly-surveillance-report, 14 October 2021., European Centre for Disease. Prevention and Control. Weekly surveillance report on COVID-19. 2021, https://www.ecdc.europa.eu/en/covid-19/surveillance/weekly-surveillance-report, 14 October 2021.
Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers
(HanushekEAWoessmannL. The economic impacts of learning losses. OECD Education Working Papers. No. 225. Paris: OECD Publishing, 2020.)
HanushekEAWoessmannL. The economic impacts of learning losses. OECD Education Working Papers. No. 225. Paris: OECD Publishing, 2020.HanushekEAWoessmannL. The economic impacts of learning losses. OECD Education Working Papers. No. 225. Paris: OECD Publishing, 2020., HanushekEAWoessmannL. The economic impacts of learning losses. OECD Education Working Papers. No. 225. Paris: OECD Publishing, 2020.
(n-tv. Hausärzte beginnen mit COVID-19-IMPFUNGEN. https://www.n-tv.de/panorama/Hausaerzte-beginnen-mit-Covid-19-Impfungen-article22470950.html. 2021.)
n-tv. Hausärzte beginnen mit COVID-19-IMPFUNGEN. https://www.n-tv.de/panorama/Hausaerzte-beginnen-mit-Covid-19-Impfungen-article22470950.html. 2021.n-tv. Hausärzte beginnen mit COVID-19-IMPFUNGEN. https://www.n-tv.de/panorama/Hausaerzte-beginnen-mit-Covid-19-Impfungen-article22470950.html. 2021., n-tv. Hausärzte beginnen mit COVID-19-IMPFUNGEN. https://www.n-tv.de/panorama/Hausaerzte-beginnen-mit-Covid-19-Impfungen-article22470950.html. 2021.
T. Dimpfl, J. Sönksen, I. Bechmann, J. Grammig (2021)
Estimation of the SARS-CoV-2 infection fatality rate in GermanyHuman Health & Disease eJournal
(RühliL. Wann schadet der CORONA-LOCKDOWN mehr, als er nützt: ETHIK und OKONOMIE als zwei SEITEN einer MEDAILLE. https://www.avenir-suisse.ch/wann-schadet-der-lockdown-mehr-als-er-nuetzt/. 2020.)
RühliL. Wann schadet der CORONA-LOCKDOWN mehr, als er nützt: ETHIK und OKONOMIE als zwei SEITEN einer MEDAILLE. https://www.avenir-suisse.ch/wann-schadet-der-lockdown-mehr-als-er-nuetzt/. 2020.RühliL. Wann schadet der CORONA-LOCKDOWN mehr, als er nützt: ETHIK und OKONOMIE als zwei SEITEN einer MEDAILLE. https://www.avenir-suisse.ch/wann-schadet-der-lockdown-mehr-als-er-nuetzt/. 2020., RühliL. Wann schadet der CORONA-LOCKDOWN mehr, als er nützt: ETHIK und OKONOMIE als zwei SEITEN einer MEDAILLE. https://www.avenir-suisse.ch/wann-schadet-der-lockdown-mehr-als-er-nuetzt/. 2020.
Questions and answers on COVID-19 vaccination in the EU
(AumSLeeSYShinY. COVID-19 doesn’t need lockdowns to destroy jobs: the effect of local outbreaks in Korea. NBER Working Paper No. 27264. Cambridge, MA, 2020.)
AumSLeeSYShinY. COVID-19 doesn’t need lockdowns to destroy jobs: the effect of local outbreaks in Korea. NBER Working Paper No. 27264. Cambridge, MA, 2020.AumSLeeSYShinY. COVID-19 doesn’t need lockdowns to destroy jobs: the effect of local outbreaks in Korea. NBER Working Paper No. 27264. Cambridge, MA, 2020., AumSLeeSYShinY. COVID-19 doesn’t need lockdowns to destroy jobs: the effect of local outbreaks in Korea. NBER Working Paper No. 27264. Cambridge, MA, 2020.
(WuZMcGooganJM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA2020; 323(13): 1239–1242.32091533)
WuZMcGooganJM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA2020; 323(13): 1239–1242.32091533WuZMcGooganJM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA2020; 323(13): 1239–1242.32091533, WuZMcGooganJM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA2020; 323(13): 1239–1242.32091533
(2021)
Schul- und Kitaschließungen, Krankheit, Quarantäne – die coronabedingten Arbeitsausfälle der Erwerbstätigen steigen auf 59,2
T. Denoeux (2018)
Decision-Making with Belief Functions: a ReviewArXiv, abs/1808.05322
(2020)
Institut. Archiv der Situationsberichte des Robert Koch-Instituts zu COVID-19
(CNBC. Pfizer CEO says third covid vaccine dose likely needed within 12 months. https://www.cnbc.com/2021/04/15/pfizer-ceo-says-third-covid-vaccine-dose-likely-needed-within-12-months.html. 2021.)
CNBC. Pfizer CEO says third covid vaccine dose likely needed within 12 months. https://www.cnbc.com/2021/04/15/pfizer-ceo-says-third-covid-vaccine-dose-likely-needed-within-12-months.html. 2021.CNBC. Pfizer CEO says third covid vaccine dose likely needed within 12 months. https://www.cnbc.com/2021/04/15/pfizer-ceo-says-third-covid-vaccine-dose-likely-needed-within-12-months.html. 2021., CNBC. Pfizer CEO says third covid vaccine dose likely needed within 12 months. https://www.cnbc.com/2021/04/15/pfizer-ceo-says-third-covid-vaccine-dose-likely-needed-within-12-months.html. 2021.
(WongCHSiahKWLoAW. Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics. medRxiv, 2020.)
WongCHSiahKWLoAW. Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics. medRxiv, 2020.WongCHSiahKWLoAW. Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics. medRxiv, 2020., WongCHSiahKWLoAW. Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics. medRxiv, 2020.
Rechnen mit Wirtschaftswachstum von 3,5% in 2021 und 3,6% in 2022
R. Challen, E. Brooks-Pollock, J. Read, L. Dyson, K. Tsaneva-Atanasova, L. Danon (2021)
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort studyThe BMJ, 372
(Robert Koch Institut. Archiv der Situationsberichte des Robert Koch-Instituts zu COVID-19. August 2020, https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv_August.html.)
Robert Koch Institut. Archiv der Situationsberichte des Robert Koch-Instituts zu COVID-19. August 2020, https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv_August.html.Robert Koch Institut. Archiv der Situationsberichte des Robert Koch-Instituts zu COVID-19. August 2020, https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv_August.html., Robert Koch Institut. Archiv der Situationsberichte des Robert Koch-Instituts zu COVID-19. August 2020, https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv_August.html.
(2020)
Wann schadet der CORONA-LOCKDOWN mehr, als er nützt: ETHIK und OKONOMIE als zwei SEITEN einer MEDAILLE
(JohnJKoerberFSchadM. Differential discounting in the economic evaluation of healthcare programs. Cost Eff Resour Alloc2019; 17: 29.31866768)
JohnJKoerberFSchadM. Differential discounting in the economic evaluation of healthcare programs. Cost Eff Resour Alloc2019; 17: 29.31866768JohnJKoerberFSchadM. Differential discounting in the economic evaluation of healthcare programs. Cost Eff Resour Alloc2019; 17: 29.31866768, JohnJKoerberFSchadM. Differential discounting in the economic evaluation of healthcare programs. Cost Eff Resour Alloc2019; 17: 29.31866768
(2021)
Quarantäne -die coronabedingten Arbeitsausfälle der Erwerbstätigen steigen auf 59,2 Millionen Arbeitstage. IAB-Forum
(Organisation for Economic Co-operation and Development. Level of GDP per capita and productivity. https://stats.oecd.org/Index.aspx?DataSetCode=PDB_LV.)
Organisation for Economic Co-operation and Development. Level of GDP per capita and productivity. https://stats.oecd.org/Index.aspx?DataSetCode=PDB_LV.Organisation for Economic Co-operation and Development. Level of GDP per capita and productivity. https://stats.oecd.org/Index.aspx?DataSetCode=PDB_LV., Organisation for Economic Co-operation and Development. Level of GDP per capita and productivity. https://stats.oecd.org/Index.aspx?DataSetCode=PDB_LV.
M. Abers, D. Musher (2014)
Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics.QJM : monthly journal of the Association of Physicians, 107 7
(2021)
Altmaier: „Rechnen mit Wirtschaftswachstum von 3,5% in 2021 und 3,6% in 2022“
W. Cornwall (2020)
Can you put a price on COVID-19 options? Experts weigh lives versus economicsScience
(2020)
Remarks by commissioner gentiloni at the press conference on the Autumn 2020 economic forecast
(2021)
Race to the vaccine: a COVID-19 vaccine life cycle: from DNA to doses
(Tagesschau.de. Umfrage bei Gesundheitsämtern. Fünf Kontaktpersonen pro Corona-Infiziertem., https://www.tagesschau.de/investigativ/ndr-wdr/gesundheitsaemter-kontaktpersonen-101.html. 2020)
Tagesschau.de. Umfrage bei Gesundheitsämtern. Fünf Kontaktpersonen pro Corona-Infiziertem., https://www.tagesschau.de/investigativ/ndr-wdr/gesundheitsaemter-kontaktpersonen-101.html. 2020Tagesschau.de. Umfrage bei Gesundheitsämtern. Fünf Kontaktpersonen pro Corona-Infiziertem., https://www.tagesschau.de/investigativ/ndr-wdr/gesundheitsaemter-kontaktpersonen-101.html. 2020, Tagesschau.de. Umfrage bei Gesundheitsämtern. Fünf Kontaktpersonen pro Corona-Infiziertem., https://www.tagesschau.de/investigativ/ndr-wdr/gesundheitsaemter-kontaktpersonen-101.html. 2020
(DeatonA. Ein freier Markt garantiert keine GESUNDHEITSVERSORGUNG. Die Zeit. https://www.zeit.de/wirtschaft/2020-04/angus-deaton-usa-oekonomie-deaths-of-despair. 2020.)
DeatonA. Ein freier Markt garantiert keine GESUNDHEITSVERSORGUNG. Die Zeit. https://www.zeit.de/wirtschaft/2020-04/angus-deaton-usa-oekonomie-deaths-of-despair. 2020.DeatonA. Ein freier Markt garantiert keine GESUNDHEITSVERSORGUNG. Die Zeit. https://www.zeit.de/wirtschaft/2020-04/angus-deaton-usa-oekonomie-deaths-of-despair. 2020., DeatonA. Ein freier Markt garantiert keine GESUNDHEITSVERSORGUNG. Die Zeit. https://www.zeit.de/wirtschaft/2020-04/angus-deaton-usa-oekonomie-deaths-of-despair. 2020.
(European Medicines Agency. Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers, https://www.ema.europa.eu/en/news/adapting-covid-19-vaccines-sars-cov-2-variants-guidance-vaccine-manufacturers. 2021.)
European Medicines Agency. Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers, https://www.ema.europa.eu/en/news/adapting-covid-19-vaccines-sars-cov-2-variants-guidance-vaccine-manufacturers. 2021.European Medicines Agency. Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers, https://www.ema.europa.eu/en/news/adapting-covid-19-vaccines-sars-cov-2-variants-guidance-vaccine-manufacturers. 2021., European Medicines Agency. Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers, https://www.ema.europa.eu/en/news/adapting-covid-19-vaccines-sars-cov-2-variants-guidance-vaccine-manufacturers. 2021.
(DW. COVID: why experts say herd immunity is still out of reach. https://www.dw.com/en/covid-why-experts-say-herd-immunity-is-still-out-of-reach/a-57860285. 2021.)
DW. COVID: why experts say herd immunity is still out of reach. https://www.dw.com/en/covid-why-experts-say-herd-immunity-is-still-out-of-reach/a-57860285. 2021.DW. COVID: why experts say herd immunity is still out of reach. https://www.dw.com/en/covid-why-experts-say-herd-immunity-is-still-out-of-reach/a-57860285. 2021., DW. COVID: why experts say herd immunity is still out of reach. https://www.dw.com/en/covid-why-experts-say-herd-immunity-is-still-out-of-reach/a-57860285. 2021.
(Robert KochInstitut. October 8, 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html.)
Robert KochInstitut. October 8, 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html.Robert KochInstitut. October 8, 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html., Robert KochInstitut. October 8, 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html.
Chi Wong, K. Siah, A. Lo (2020)
Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective TherapeuticsmedRxiv
M. Preziosi, M. Preziosi, M. Halloran (2003)
Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37 6
(WDR. Millionenplan für CORONA-IMPFUNGEN in NRW, https://www1.wdr.de/nachrichten/landespolitik/corona-impfstoff-112.html. 2020.)
WDR. Millionenplan für CORONA-IMPFUNGEN in NRW, https://www1.wdr.de/nachrichten/landespolitik/corona-impfstoff-112.html. 2020.WDR. Millionenplan für CORONA-IMPFUNGEN in NRW, https://www1.wdr.de/nachrichten/landespolitik/corona-impfstoff-112.html. 2020., WDR. Millionenplan für CORONA-IMPFUNGEN in NRW, https://www1.wdr.de/nachrichten/landespolitik/corona-impfstoff-112.html. 2020.
J. John, F. Koerber, M. Schad (2019)
Differential discounting in the economic evaluation of healthcare programsCost Effectiveness and Resource Allocation : C/E, 17
(2000)
Vorausberechneter Bevölkerungsstand. Moderate Entwicklung der Geburtenhäufigkeit, Lebenserwartung und Wanderung (G2L2W2). Federal Office of Statistics
(Handelsblatt. Die vier zugelassenen impfstoffe im VERGLEICH. https://www.handelsblatt.com/technik/medizin/biontech-moderna-astrazeneca-und-johnson-und-johnson-die-vier-zugelassenen-impfstoffe-im-vergleich/26767438.html?ticket=ST-9748737-tLgmvxqXWfoQLlY5P9g2-ap2. 2021.)
Handelsblatt. Die vier zugelassenen impfstoffe im VERGLEICH. https://www.handelsblatt.com/technik/medizin/biontech-moderna-astrazeneca-und-johnson-und-johnson-die-vier-zugelassenen-impfstoffe-im-vergleich/26767438.html?ticket=ST-9748737-tLgmvxqXWfoQLlY5P9g2-ap2. 2021.Handelsblatt. Die vier zugelassenen impfstoffe im VERGLEICH. https://www.handelsblatt.com/technik/medizin/biontech-moderna-astrazeneca-und-johnson-und-johnson-die-vier-zugelassenen-impfstoffe-im-vergleich/26767438.html?ticket=ST-9748737-tLgmvxqXWfoQLlY5P9g2-ap2. 2021., Handelsblatt. Die vier zugelassenen impfstoffe im VERGLEICH. https://www.handelsblatt.com/technik/medizin/biontech-moderna-astrazeneca-und-johnson-und-johnson-die-vier-zugelassenen-impfstoffe-im-vergleich/26767438.html?ticket=ST-9748737-tLgmvxqXWfoQLlY5P9g2-ap2. 2021.
(WangerSWeberE. Schul- und Kitaschließungen, Krankheit, Quarantäne – die coronabedingten Arbeitsausfälle der Erwerbstätigen steigen auf 59,2 Millionen Arbeitstage. IAB-Forum2021.)
WangerSWeberE. Schul- und Kitaschließungen, Krankheit, Quarantäne – die coronabedingten Arbeitsausfälle der Erwerbstätigen steigen auf 59,2 Millionen Arbeitstage. IAB-Forum2021.WangerSWeberE. Schul- und Kitaschließungen, Krankheit, Quarantäne – die coronabedingten Arbeitsausfälle der Erwerbstätigen steigen auf 59,2 Millionen Arbeitstage. IAB-Forum2021., WangerSWeberE. Schul- und Kitaschließungen, Krankheit, Quarantäne – die coronabedingten Arbeitsausfälle der Erwerbstätigen steigen auf 59,2 Millionen Arbeitstage. IAB-Forum2021.
E. Damuth, Jessica Mitchell, Jason Bartock, B. Roberts, S. Trzeciak (2015)
Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis.The Lancet. Respiratory medicine, 3 7
K. Twohig, T. Nyberg, A. Zaidi, S. Thelwall, M. Sinnathamby, S. Aliabadi, S. Seaman, Ross Harris, R. Hope, J. Lopez-Bernal, E. Gallagher, A. Charlett, D. Angelis, A. Presanis, G. Dabrera, Cherian Fairle, C. Koshy, Amy Ash, E. Wise, N. Moore, M. Mori, N. Cortes, J. Lynch, S. Kidd, D. Fairley, T. Curran, J. McKenna, Helen Adams, C. Fraser, Tanya Golubchik, D. Bonsall, M. Hassan-Ibrahim, Cassandra Malone, Benjamin Cogger, Michelle Wantoch, N. Reynolds, B. Warne, Joshua Maksimovic, Karla Spellman, Kathryn Mccluggage, Michael John, Robert Beer, Safiah Afifi, Sian Morgan, A. Marchbank, A. Price, C. Kitchen, Huw Gulliver, I. Merrick, Joel Southgate, Martyn Guest, R. Munn, T. Workman, T. Connor, William Fuller, Catherine Bresner, L. Snell, A. Patel, T. Charalampous, G. Nebbia, R. Batra, J. Edgeworth, S. Robson, A. Beckett, D. Aanensen, A. Underwood, C. Yeats, Khalil AbuDahab, Ben Taylor, Mirko Menegazzo, G. Clark, W. Smith, Manjinder Khakh, Vicki Fleming, M. Lister, H. Howson-Wells, L. Berry, T. Boswell, A. Joseph, Iona Willingham, Carl Jones, C. Holmes, P. Bird, Thomas Helmer, K. Fallon, Julian Tang, Veena Raviprakash, Sharon Campbell, Nicola Sheriff, Victoria Blakey, L. Williams, M. Loose, N. Holmes, Christopher Moore, M. Carlile, Victoria Wright, Fei Sang, Johnny Debebe, Francesc Coll, A. Signell, G. Betancor, H. Wilson, Sahar Eldirdiri, A. Kenyon, Thomas Davis, O. Pybus, L. Plessis, A. Zarebski, J. Raghwani, M. Kraemer, Sarah François, S. Attwood, T. Vasylyeva, Marina Zamudio, B. Gutiérrez, M. Torok, W. Hamilton, I. Goodfellow, G. Hall, A. Jahun, Y. Chaudhry, M. Hosmillo, M. Pinckert, I. Georgana, S. Moses, Hannah Lowe, L. Bedford, J. Moore, Susanne Stonehouse, Chloe Fisher, A. Awan, John Boyes, Judith Breuer, K. Harris, Julianne Brown, D. Shah, Laura Atkinson, Jack Lee, N. Storey, F. Flaviani, A. Alcolea-Medina, Rebecca Williams, G. Vernet, Michael Chapman, L. Levett, J. Heaney, W. Chatterton, Monika Pusok, Li Xu-McCrae, Darren Smith, M. Bashton, G. Young, A. Holmes, P. Randell, A. Cox, P. Madona, F. Bolt, James Price, S. Mookerjee, M. Ragonnet-Cronin, Fabricia Nascimento, D. Jorgensen, Igor Siveroni, Robert Johnson, O. Boyd, L. Geidelberg, E. Volz, A. Rowan, G. Taylor, Katherine Smollett, N. Loman, J. Quick, C. McMurray, Joanne Stockton, S. Nicholls, W. Rowe, Radoslaw Poplawski, A. McNally, Rocio Nunez, J. Mason, T. Robinson, E. O’Toole, Joanne Watts, Cathy Breen, A. Cowell, Graciela Sluga, N. Machin, Shazaad Ahmad, R. George, F. Halstead, V. Sivaprakasam, Wendy Hogsden, C. Illingworth, Christopher Jackson, E. Thomson, J. Shepherd, Patawee Asamaphan, M. Niebel, Kathy Li, Rajiv Shah, N. Jesudason, Lily Tong, A. Broos, Daniel Mair, Jenna Nichols, Stephen Carmichael, K. Nomikou, Elihu Aranday-Cortes, N. Johnson, Igor Starinskij, A. Filipe, David Robertson, R. Orton, J. Hughes, S. Vattipally, J. Singer, Seema Nickbakhsh, A. Hale, L. Macfarlane-Smith, Katherine Harper, H. Carden, Y. Taha, Brendan Payne, S. Burton-Fanning, S. Waugh, J. Collins, G. Eltringham, S. Rushton, S. O'Brien, A. Bradley, A. Maclean, Guy Mollett, Rachel Blacow, K. Templeton, M. McHugh, R. Dewar, Elizabeth Wastenge, S. Dervisevic, Rachael Stanley, E. Meader, L. Coupland, Louise Smith, Clive Graham, E. Barton, D. Padgett, Garren Scott, E. Swindells, J. Greenaway, Andrew Nelson, C. McCann, W. Yew, M. Andersson, T. Peto, A. Justice, D. Eyre, D. Crook, T. Sloan, Nichola Duckworth, Sarah Walsh, A. Chauhan, S. Glaysher, K. Bicknell, S. Wyllie, S. Elliott, Allyson Lloyd, R. Impey, Nick Levene, Lynn Monaghan, D. Bradley, Tim Wyatt, E. Allara, C. Pearson, H. Osman, A. Bosworth, E. Robinson, P. Muir, I. Vipond, R. Hopes, Hannah Pymont, S. Hutchings, M. Curran, S. Parmar, A. Lackenby, T. Mbisa, S. Platt, S. Miah, D. Bibby, C. Manso, Jonathan Hubb, M. Chand, G. Dabrera, M. Ramsay, D. Bradshaw, A. Thornton, R. Myers, Ulf Schaefer, N. Groves, E. Gallagher, David Lee, David Williams, N. Ellaby, Ian Harrison, H. Hartman, Nikos Manesis, Vineet Patel, Chloe Bishop, V. Chalker, J. Ledesma, K. Twohig, M. Holden, Sharif Shaaban, Alec Birchley, Alexander Adams, Alisha Davies, Amy Gaskin, Amy Plimmer, Bree Gatica-Wilcox, C. McKerr, Catherine Moore, Chris Williams, David Heyburn, E. Lacy, Ember Hilvers, Fatima Downing, Giri Shankar, H. Jones, H. Asad, J. Coombes, J. Watkins, John Evans, L. Fina, Laura Gifford, L. Gilbert, L. Graham, Malorie Perry, M. Morgan, M. Bull, M. Cronin, Nicole Pacchiarini, N. Craine, Rachel Jones, R. Howe, S. Corden, S. Rey, Sara Kumžiene-Summerhayes, Sarah Taylor, S. Cottrell, Sophie Jones, Sue Edwards, J. O’Grady, A. Page, A. Mather, D. Baker, Steven Rudder, Alp Aydin, Gemma Kay, A. Trotter, N. Alikhan, L. Martins, Thanh Le-Viet, Lizzie Meadows, A. Casey, Liz Ratcliffe, D. Simpson, Z. Molnár, T. Thompson, Erwan Acheson, J. Masoli, B. Knight, S. Ellard, C. Auckland, Christopher Jones, T. Mahungu, Dianne Irish-Tavares, T. Haque, J. Hart, E. Witele, M. Fenton, Ashok Dadrah, Amanda Symmonds, Tranprit Saluja, Y. Bourgeois, G. Scarlett, Katie Loveson, S. Goudarzi, C. Fearn, Kate Cook, Hannah Dent, Hannah Paul, David Partridge, M. Raza, C. Evans, Katie Johnson, Steven Liggett, P. Baker, S. Bonner, S. Essex, R. Lyons, K. Saeed, A. Mahanama, Buddhini Samaraweera, Siona Silveira, E. Pelosi, E. Wilson-Davies, Rachel Williams, M. Kristiansen, Sunando Roy, Charlotte Williams, Marius Cotic, N. Bayzid, Adam Westhorpe, J. Hartley, Riaz Jannoo, Helen Lowe, Angeliki Karamani, L. Ensell, J. Prieto, Sarah Jeremiah, D. Grammatopoulos, Sarojini Pandey, L. Berry, K. Jones, A. Richter, A. Beggs, A. Best, B. Percival, J. Mirza, O. Megram, M. Mayhew, L. Crawford, F. Ashcroft, E. Moles-Garcia, Nicola Cumley, Colin Smith, G. Bucca, A. Hesketh, B. Blane, Sophia Girgis, D. Leek, S. Sridhar, S. Forrest, C. Cormie, Harmeet Gill, Joana Dias, E. Higginson, Mailis Maes, Jamie Young, L. Kermack, Ravindra Gupta, C. Ludden, S. Peacock, Sophie Palmer, C. Churcher, Nazreen Hadjirin, A. Carabelli, E. Brooks, Kim Smith, Katerina Galai, Georgina McManus, C. Ruis, R. Davidson, A. Rambaut, T. Williams, Carlos Balcazar, M. Gallagher, Á. O’Toole, Stefan Rooke, V. Hill, K. Williamson, Thomas Stanton, S. Michell, C. Bewshea, B. Temperton, M. Michelsen, J. Warwick-Dugdale, R. Manley, A. Farbos, James Harrison, C. Sambles, D. Studholme, A. Jeffries, Leigh Jackson, A. Darby, J. Hiscox, S. Paterson, M. Iturriza-Gómara, K. Jackson, Anita Lucaci, Edith Vamos, M. Hughes, L. Rainbow, R. Eccles, Charlotte Nelson, Mark Whitehead, L. Turtle, S. Haldenby, R. Gregory, M. Gemmell, C. Wierzbicki, H. Webster (2021)
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort studyThe Lancet. Infectious Diseases, 22
(European Commission. Questions and answers on COVID-19 vaccination in the EU. https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans/questions-and-answers-covid-19-vaccination-eu_en. 2021.)
European Commission. Questions and answers on COVID-19 vaccination in the EU. https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans/questions-and-answers-covid-19-vaccination-eu_en. 2021.European Commission. Questions and answers on COVID-19 vaccination in the EU. https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans/questions-and-answers-covid-19-vaccination-eu_en. 2021., European Commission. Questions and answers on COVID-19 vaccination in the EU. https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans/questions-and-answers-covid-19-vaccination-eu_en. 2021.
(Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html. 2020.)
Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html. 2020.Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html. 2020., Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html. 2020.
(1951)
The generalized bayes minimax principle: a criterion for decision making under uncertainty
(LuoJ. Forecasting COVID-19 pandemic: unknown unknowns and predictive monitoring. Technol Forecast Soc Change2021; 166: 120602.33495665)
LuoJ. Forecasting COVID-19 pandemic: unknown unknowns and predictive monitoring. Technol Forecast Soc Change2021; 166: 120602.33495665LuoJ. Forecasting COVID-19 pandemic: unknown unknowns and predictive monitoring. Technol Forecast Soc Change2021; 166: 120602.33495665, LuoJ. Forecasting COVID-19 pandemic: unknown unknowns and predictive monitoring. Technol Forecast Soc Change2021; 166: 120602.33495665
E. Hanushek, Ludger Woessmann (2020)
The economic impacts of learning losses
D. Needham, V. Dinglas, O. Bienvenu, E. Colantuoni, A. Wozniak, T. Rice, Ramona Hopkins, Ramona Hopkins (2013)
One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trialThe BMJ, 346
(GarrisonLPJrMansleyECAbbottTA3rd, et al.Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report--part II. Value Health. 2010; 13(1):8–13.19883405)
GarrisonLPJrMansleyECAbbottTA3rd, et al.Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report--part II. Value Health. 2010; 13(1):8–13.19883405GarrisonLPJrMansleyECAbbottTA3rd, et al.Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report--part II. Value Health. 2010; 13(1):8–13.19883405, GarrisonLPJrMansleyECAbbottTA3rd, et al.Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report--part II. Value Health. 2010; 13(1):8–13.19883405
Aim: While the European Union (EU) has approved several COVID-19 vaccines, new variants of concern may be able to escape immunity. The purpose of this study is to project the cost-effectiveness of future lockdown policies in conjunction with a variant-adapted vaccine booster. The exemplary scenario foresees a 25% decline in the vaccine protection against severe disease. Methods: A decision model was constructed using, for example, information on age-specific fatality rates, intensive care unit (ICU) costs and outcomes, and herd protection threshold. The costs and benefits of a future lockdown strategy were determined from a societal viewpoint under three future scenarios—a booster shot’s efficacy of 0%, 50%, and 95%. Results: The cost-effectiveness ratio of a lockdown policy in conjunction with a booster dose with 95% efficacy is €44,214 per life year gained. A lockdown is cost-effective when the probability of approving a booster dose with 95% efficacy is at least 48% (76% when considering uncertainty in input factors). Conclusion: In this exemplary scenario, a future lockdown policy appears to be cost-effective if the probability of approving a variant-adapted vaccine booster with an efficacy of 95% is at least 48%.
Health Services Management Research – SAGE
Published: Feb 1, 2023
Keywords: COVID-19; Germany; revaccination; decision model
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.